Putney Financial Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Putney Financial Group’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$219K	Sell	441 -47	-10%	-$20.8K	0.2%	74
2026 Q1	$218K	Sell	488 -7	-1%	-$3.26K	0.22%	80
2025 Q4	$224K	Sell	495 -79	-14%	-$34.1K	0.21%	76
2025 Q3	$225K	Sell	574 -145	-20%	-$60.6K	0.22%	72
2025 Q2	$320K	Sell	719 -196	-21%	-$90.3K	0.32%	50
2025 Q1	$444K	Sell	915 -40	-4%	-$18.6K	0.47%	33
2024 Q4	$385K	Buy	+955	New	+$443K	0.34%	46

Other funds holding VRTX

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

BHIA

Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return

CTB

Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return

CNB

Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return

GIA

Gateway Investment Advisers Cincinnati, Ohio $10.1B AUM 40.26% 1-Year Est. Return

IFM Investors Melbourne, Australia $15.1B AUM 40.57% 1-Year Est. Return

Putney Financial Group's VRTX Position: Q2 2026 in Review

Putney Financial Group reduced its Vertex Pharmaceuticals (VRTX) stake by 9.6% in Q2 2026, selling an estimated $20.8K and leaving 441 shares worth $219K. The position accounts for 0.2% of the portfolio, ranked #74.

Putney Financial Group first reported a position in VRTX in Q4 2024 and has held it in 7 quarters since. The position peaked at $444K in Q1 2025. 334 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Putney Financial Group held 441 shares of Vertex Pharmaceuticals worth $219K as of Q2 2026.
Putney Financial Group sold 47 Vertex Pharmaceuticals shares in Q2 2026, an estimated $20.8K.
Vertex Pharmaceuticals made up 0.2% of Putney Financial Group's portfolio in Q2 2026, its #74 holding.
Putney Financial Group first reported a position in Vertex Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
Putney Financial Group's Vertex Pharmaceuticals position peaked at $444K in Q1 2025.
334 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Putney Financial Group's 13F filing for Q2 2026, filed 21 Jul 2026.